A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.

Also called NCT05952869

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 303 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05952869
  • EU CT 2022-502782-14-00
  • WHO UTN U1111-1285-4257
Other papers using this trial's data
  • Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial JAMA, 2026-01-13 DOI, PubMed 41206969, PMC12598580 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, Hong Kong SAR China, Hungary, Israel, Netherlands, New Zealand, Norway, Singapore, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05952869. Randomized; triple masking; primary purpose treatment. Start 2023-08-08 (actual); primary completion 2025-04-07 (actual). Results posted on 2026-02-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
Condition
Hypercholesterolemia
Intervention (Drug)
Enlicitide Decanoate
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct05952869
Content hash
e6275873d5a5c8f806b671b1d81e826b5f25dd39d8ab35b44864e2e617f6970c